Pharmafile Logo

Webcast: Biosimilars: Friend or Foe to Healthcare?

March 31, 2015 | Biologics 

Understanding the opportunities for biosimilars and the threats to innovator biologics

Referencing recent findings from our Therapy Watch syndicated study in RA, this webcast investigates physicians’ perceptions of the biosimilars market. Therapy Watch Director Allison Fleetwood and Access Partnership Director Shrinivas Rao Mukku interview a major US payer, who offers expert opinion on the opportunities for biosimilars in the US market, the possible threats to originator brands, and consider what companies entering the market need to do to effectively launch their follow-on biologic.

Furthermore, this webcast looks into how the launch of mAb biosimilars in Europe may impact on healthcare strategies in the US, and how to overcome the challenges biosimilars face if they are to achieve sufficient uptake.

What you will learn:

  • Better understand physician awareness and familiarity with biosimilars and the potential barriers to uptake 
  • Learn about the strengths and weaknesses of biosimilars and the impact they may have on the treatment landscape from the payer perspective 
  • Gain greater insight into what companies entering the market need to do to effectively launch their follow-on biologic

To view this webinar please visit http://bit.ly/WBnezg 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Infographic: Are data blind spots putting your launch at risk?

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

From activity to impact: 5 takeaways from MAPS Americas 2026

Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…

Inizio launches Intelligent Congress: Turning medical event investment into measurable impact

Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…

Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

5 takeaways from Reuters’ Pharma USA 2026 – and what they mean for you

Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercializationâ„¢. Now we’re back in the…

Precision Medical Affairs in Action: Using AI and Analytics to Elevate Strategy, Engagement, and Impact

Discover how AI, analytics and real-world data are reshaping Medical Affairs.

How did multifaceted support from across Inizio help a biotech firm prepare for launch?

Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success.

Our key takeaways from ISMPP EU 2026 – Evolving with Purpose: Excellence in an Era of Efficiency

Explore Inizio Medical’s key takeaway from ISMPP EU 2026, including AI governance, transparency, patient partnership and evolving impact measurement.